UK’s Biofidelity secures €22M from Octopus Ventures, others: Know more
Cambridge-based Biofidelity, a commercial-stage genomic technology company, announced on Wednesday, April 3, that it has secured $24M (approximately €22M) in a fresh funding round, bringing the total funding raised to $60M (approximately €55.3M).